[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100591144":3},{"organization":4,"armGroups":7,"interventions":7,"overallOfficials":8,"centralContacts":12,"locations":18,"responsibleParty":104,"collaborators":7,"id":106,"slug":7,"hasResults":107,"nctId":108,"briefTitle":109,"officialTitle":110,"acronym":111,"eligibilityCriteria":112,"healthyVolunteers":107,"sex":113,"minAge":114,"maxAge":115,"enrollmentInfo":116,"targetDuration":119,"studyType":120,"phases":7,"briefSummary":121,"conditions":122,"keywords":126,"overallStatus":21,"whyStopped":7,"lastUpdateSubmitDate":142,"lastUpdatePostDateStruct":143,"startDateStruct":146,"completionDateStruct":148,"leadSponsor":150,"locationsCount":151},{"fullName":5,"class":6},"Lexeo Therapeutics","INDUSTRY",null,[9],{"name":10,"affiliation":5,"role":11},"Lexeo Clinical Trials","STUDY_DIRECTOR",[13],{"name":14,"role":15,"phone":16,"phoneExt":7,"email":17},"Person*: Lexeo Clinical Trials","CONTACT","212-547-9879","clinicaltrials@lexeotx.com",[19,37,52,64,79,91],{"facility":20,"status":21,"city":22,"state":23,"zip":24,"country":25,"cosmosGeoPoint":26,"geoPoint":31,"contacts":32},"Leland Stanford Junior University","RECRUITING","Redwood City","California","94063-3126","United States",{"type":27,"coordinates":28},"Point",[29,30],-122.23635,37.48522,{"lat":30,"lon":29},[33],{"name":34,"role":15,"phone":35,"phoneExt":7,"email":36},"Priya Nair","512-217-3812","ashas@stanford.edu",{"facility":38,"status":21,"city":39,"state":40,"zip":41,"country":25,"cosmosGeoPoint":42,"geoPoint":46,"contacts":47},"Johns Hopkins University","Baltimore","Maryland","21287",{"type":27,"coordinates":43},[44,45],-76.61219,39.29038,{"lat":45,"lon":44},[48],{"name":49,"role":15,"phone":50,"phoneExt":7,"email":51},"Crystal Tichnell","410-502-7161","ctichne1@jhmi.edu",{"facility":53,"status":21,"city":54,"state":40,"zip":55,"country":25,"cosmosGeoPoint":56,"geoPoint":60,"contacts":61},"Northshore University Healthsystem Research Institute","Columbia","21044",{"type":27,"coordinates":57},[58,59],-76.83942,39.24038,{"lat":59,"lon":58},[62],{"name":7,"role":15,"phone":7,"phoneExt":7,"email":63},"bprindeville@northshore.org",{"facility":65,"status":21,"city":66,"state":67,"zip":68,"country":25,"cosmosGeoPoint":69,"geoPoint":73,"contacts":74},"University of Michigan","Ann Arbor","Michigan","48109",{"type":27,"coordinates":70},[71,72],-83.74088,42.27756,{"lat":72,"lon":71},[75],{"name":76,"role":15,"phone":77,"phoneExt":7,"email":78},"Muhammad Hussain","734-765-8217","muhammhu@med.umich.edu",{"facility":80,"status":21,"city":81,"state":67,"zip":82,"country":25,"cosmosGeoPoint":83,"geoPoint":87,"contacts":88},"Henry Ford Hospital","Detroit","48202",{"type":27,"coordinates":84},[85,86],-83.04575,42.33143,{"lat":86,"lon":85},[89],{"name":7,"role":15,"phone":7,"phoneExt":7,"email":90},"wcabral1@hfhs.org",{"facility":92,"status":21,"city":93,"state":94,"zip":95,"country":25,"cosmosGeoPoint":96,"geoPoint":100,"contacts":101},"University of Rochester","Rochester","New York","14642",{"type":27,"coordinates":97},[98,99],-77.61556,43.15478,{"lat":99,"lon":98},[102],{"name":7,"role":15,"phone":7,"phoneExt":7,"email":103},"lori_caufield@urmc.rochester.edu",{"type":105,"investigatorFullName":7,"investigatorTitle":7,"investigatorAffiliation":7,"oldNameTitle":7,"oldOrganization":7},"SPONSOR","100591144",false,"NCT06976606","A Study to Assess Real-world Patient Characteristics and Clinical Course for Symptomatic Patients With PKP2-ACM","An Observational Study to Assess Real-world Patient Characteristics, Clinical Course, and Treatment Patterns for Symptomatic Patients With Arrhythmogenic Cardiomyopathy (ACM) Due To a PlaKoPhilin-2 Pathogenic Variant (PKP2)","SNAPSHOT- PKP2","Inclusion Criteria:\n\n* Adults with a clinical diagnosis of ACM as defined by the 2010 revised Task Force Criteria (TFC)\n* Documentation of a pathogenic or likely pathogenic truncating variant in PKP2\n* Frequent premature ventricular contractions (PVCs)\n* Patients must have an ICD placed prior to enrollment\n* Left ventricular ejection fraction (LVEF) ≥ 50% for Part A participants. Left ventricular ejection fraction (LVEF) ≥40% for Part B participants.\n\nExclusion Criteria:\n\n* Evidence of variant(s) in addition to PKP2 that meet standard criteria to be considered pathogenic or likely pathogenic for an arrhythmogenic cardiomyopathy.\n* A history of other cardiac abnormalities as specified in the protocol.\n* New York Heart Association symptoms of heart failure of Class IV at the time of consent.\n* A history of prior gene transfer therapy.","ALL","18 Years","65 Years",{"count":117,"type":118},40,"ESTIMATED","1 Year","OBSERVATIONAL","An observational study to assess real-world patient characteristics and clinical course of disease in participants with PKP2-ACM.",[123,124,125],"Arrhythmogenic Cardiomyopathy","PKP2-ACM","PKP2-ARVC",[123,127,128,129,130,131,132,133,134,135,136,137,138,139,140,141],"ACM","Cardiomyopathy","ARVC","Arrhythmogenic Right Ventricular","Arrhythmogenic Right Ventricular Dysplasia","Genetic cardiomyopathy","Gene Therapy","PKP2 Gene","Plakophilin-2","LX2020","SNAPSHOT-PKP2","Ventricular Arrhythmia","PVCs","Sudden Cardiac Death","Cardiac Arrest","2025-05-13",{"date":144,"type":145},"2025-05-16","ACTUAL",{"date":147,"type":145},"2024-01-23",{"date":149,"type":118},"2027-09",{"name":5,"class":6},6]